Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Rituximab
MabThera
Routinely available
SMC (675/11)
02/03/2011
Indication
Follicular lymphoma patients responding to induction therapy
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
100mg/10mL, 500mg/50mL concentrate for solution for infusion
Comments
March 2011 - Added to the Additional List, for Specialist Use only.